CURRENT PHARMACOTHERAPY FOR SYSTEMIC JUVENILE ARTHRITIS
Systemic juvenile arthritis (sJA) is one of the severest childhood somatic diseases. The relevance of the problem associated with sJA is determined by difficulties in early diagnosis, by the rapid development of disability, and by poor prognosis with a high risk for life-threatening conditions. It s...
Main Authors: | I. P. Nikishina, M. I. Kaleda |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA PRESS LLC
2015-03-01
|
Series: | Научно-практическая ревматология |
Subjects: | |
Online Access: | https://rsp.mediar-press.net/rsp/article/view/2043 |
Similar Items
-
Modern pharmacotherapy of psoriatic arthritis
by: Yu. L. Korsakova, et al.
Published: (2019-03-01) -
Real-world data reveals the complexity of disease modifying anti-rheumatic drug treatment patterns in juvenile idiopathic arthritis: an observational study
by: Luiza R. Grazziotin, et al.
Published: (2022-04-01) -
MACROPHAGE ACTIVATION SYNDROME IN PATIENTS WITH SYSTEMIC JUVENILE ARTHRITIS
by: S. R. Rodionovskaya, et al.
Published: (2014-06-01) -
Economic evaluation of infliximab, synthetic triple therapy and methotrexate in the treatment of newly diagnosed juvenile idiopathic arthritis
by: Maarit Tarkiainen, et al.
Published: (2022-11-01) -
Gene engineering biological therapy for juvenile arthritis
by: Kh Mikhel's, et al.
Published: (2011-02-01)